Ronit Mazor
Overview
Explore the profile of Ronit Mazor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
527
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bing S, Seirup M, Hoang T, Najera S, Britten C, Warrington S, et al.
Nat Biomed Eng
. 2023 Nov;
8(2):193-200.
PMID: 37996615
Owing to the immunogenicity of adeno-associated viruses (AAVs), gene therapies using AAVs face considerable obstacles. Here, by leveraging ex vivo T-cell assays, the prediction of epitope binding to major histocompatibility...
2.
Bing S, Warrington S, Mazor R
Front Immunol
. 2023 Jul;
14:1211529.
PMID: 37469509
During gene therapy trials, immune responses against adeno-associated virus (AAV) vectors are monitored by antibody assays that detect the humoral and T-cell mediated cellular responses to AAV vectors. T cell...
3.
Bing S, Justesen S, Wu W, Sajib A, Warrington S, Baer A, et al.
Mol Ther Methods Clin Dev
. 2022 Feb;
24:255-267.
PMID: 35211638
Despite the high safety profile demonstrated in clinical trials, the immunogenicity of adeno-associated virus (AAV)-mediated gene therapy remains a major hurdle. Specifically, T-cell-mediated immune responses to AAV vectors are related...
4.
Shan L, van Dyk N, Haskins N, Cook K, Rosenthal K, Mazor R, et al.
Commun Biol
. 2021 Sep;
4(1):1048.
PMID: 34497355
In a biologic therapeutic landscape that requires versatility in targeting specificity, valency and half-life modulation, the monomeric Fc fusion platform holds exciting potential for the creation of a class of...
5.
Mazor R, Pastan I
Front Immunol
. 2020 Jul;
11:1261.
PMID: 32695104
Immunotoxins are cytolytic fusion proteins developed for cancer therapy, composed of an antibody fragment that binds to a cancer cell and a protein toxin fragment that kills the cell. exotoxin...
6.
Leshem Y, King E, Mazor R, Reiter Y, Pastan I
Toxins (Basel)
. 2018 Nov;
10(11).
PMID: 30441807
SS1P is an anti-mesothelin immunotoxin composed of a targeting antibody fragment genetically fused to a truncated fragment of Pseudomonas exotoxin A. Delayed responses reported in mesothelioma patients receiving SS1P suggest...
7.
Mazor R, King E, Pastan I
Cell Immunol
. 2018 Sep;
334:38-41.
PMID: 30213644
LMB-100 is a recombinant immunotoxin being developed for cancer treatment that is composed of a Fab that binds to mesothelin and a portion of Pseudomonas exotoxin A. LMB-100 is in...
8.
Mazor R, King E, Pastan I
Am J Pathol
. 2018 Jun;
188(8):1736-1743.
PMID: 29870741
Recombinant immunotoxins (RITs) are genetically engineered proteins being developed to treat cancer. They are composed of an Fv that targets a cancer antigen and a fragment of a bacterial toxin...
9.
Kaplan G, Mazor R, Lee F, Jang Y, Leshem Y, Pastan I
Mol Cancer Ther
. 2018 Apr;
17(7):1486-1493.
PMID: 29695631
Tac (CD25) is expressed on multiple hematologic malignancies and is a target for cancer therapies. LMB-2 is an extremely active anti-Tac recombinant immunotoxin composed of an Fv that binds to...
10.
King E, Mazor R, Cuburu N, Pastan I
J Immunol
. 2018 Feb;
200(6):2038-2045.
PMID: 29431691
Recombinant immunotoxins (RITs) are chimeric proteins being developed for cancer treatment. They are composed of an Ab fragment that targets a cancer Ag and a cytotoxic portion of exotoxin A....